AU748496B2 - Local delivery of long lasting therapeutic agents - Google Patents

Local delivery of long lasting therapeutic agents Download PDF

Info

Publication number
AU748496B2
AU748496B2 AU34527/99A AU3452799A AU748496B2 AU 748496 B2 AU748496 B2 AU 748496B2 AU 34527/99 A AU34527/99 A AU 34527/99A AU 3452799 A AU3452799 A AU 3452799A AU 748496 B2 AU748496 B2 AU 748496B2
Authority
AU
Australia
Prior art keywords
agents
peptide
derivative
nhs
reactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34527/99A
Other languages
English (en)
Other versions
AU3452799A (en
Inventor
Dominique P Bridon
Alan M. Ezrin
Darren L. Holmes
Peter G. Milner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Inc
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Publication of AU3452799A publication Critical patent/AU3452799A/en
Application granted granted Critical
Publication of AU748496B2 publication Critical patent/AU748496B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU34527/99A 1998-03-23 1999-03-23 Local delivery of long lasting therapeutic agents Ceased AU748496B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US7897498P 1998-03-23 1998-03-23
US60/078974 1998-03-23
US8635298P 1998-05-20 1998-05-20
US60/086352 1998-05-20
US8620598P 1998-05-21 1998-05-21
US60/086205 1998-05-21
US10739198P 1998-11-06 1998-11-06
US60/107391 1998-11-06
PCT/US1999/006344 WO1999048536A2 (fr) 1998-03-23 1999-03-23 Apport local d'agents therapeutiques a action prolongee

Publications (2)

Publication Number Publication Date
AU3452799A AU3452799A (en) 1999-10-18
AU748496B2 true AU748496B2 (en) 2002-06-06

Family

ID=27491437

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34527/99A Ceased AU748496B2 (en) 1998-03-23 1999-03-23 Local delivery of long lasting therapeutic agents

Country Status (6)

Country Link
EP (1) EP1042003A1 (fr)
JP (1) JP2002512640A (fr)
AU (1) AU748496B2 (fr)
CA (1) CA2291066A1 (fr)
IL (1) IL133053A0 (fr)
WO (1) WO1999048536A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101222904B1 (ko) 1993-07-19 2013-01-17 안지오테크 파마슈티칼즈, 인코포레이티드 항맥관형성 조성물, 당해 조성물로 피복된 스텐트 및 당해 스텐트의 제조방법
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
CA2501421A1 (fr) 1999-05-17 2000-11-23 Conjuchem Inc. Exendin-4 a longue duree d'action
CN1351611A (zh) 1999-05-17 2002-05-29 康久化学公司 病毒感染的长效融合肽抑制剂
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DK1105409T3 (da) * 1999-05-17 2006-07-03 Conjuchem Inc Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter
CA2373252C (fr) * 1999-05-17 2007-08-07 Conjuchem Inc. Peptides antiangiogeniques durables
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
CA2383794A1 (fr) * 1999-09-07 2001-03-15 Conjuchem Inc. Methodes et compositions destinees a la production d'agents anticancereux a activite prolongee
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
EP1889639A3 (fr) * 1999-09-07 2008-04-09 ConjuChem Biotechnologies Inc. Procédés et compositions pour produire des agents antinéoplastiques de très longue durée
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6380405B1 (en) * 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
EP1355941A2 (fr) 2001-02-02 2003-10-29 ConjuChem, Inc. Derives du facteur de liberation de l'hormone de croissance de longue duree
US7112567B2 (en) 2001-02-16 2006-09-26 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
JP4668510B2 (ja) * 2001-09-29 2011-04-13 持田製薬株式会社 可撓性容器入り局所止血用医薬組成物
EP1747233A4 (fr) * 2004-05-06 2007-04-25 Composes pour cible virale specifique
JP2008520546A (ja) * 2004-09-21 2008-06-19 アドバンスト メディカル オプティクス， インコーポレーテッド 粘弾性溶液またはゲル製剤およびそれを使って身体部位を処置する方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010302A1 (fr) * 1993-10-15 1995-04-20 Redcell, Inc. Proteine serique et cellulaire d'ancrage et conjugues
WO1998000171A2 (fr) * 1996-07-01 1998-01-08 Conjuchem, Inc. Excipients endogenes conjugues prolongeant la duree de vie des anti-thrombines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883650A (en) * 1988-04-13 1989-11-28 Albert Einstein College Of Medicine - Of Yeshiva University Radioidohippuric acid ester, a conjugate thereof, and methods of making the same
JPH04364200A (ja) * 1991-06-10 1992-12-16 Unitika Ltd 細胞接着性アルブミン
IL108388A0 (en) * 1993-01-21 1994-04-12 Harvard College Amplified direction of effector groups to specific target cells in an animal
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
DE19505960A1 (de) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
ATE216402T1 (de) * 1997-11-07 2002-05-15 Conjuchem Inc Opioid-konjugate mit endogenen trägerproteinen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010302A1 (fr) * 1993-10-15 1995-04-20 Redcell, Inc. Proteine serique et cellulaire d'ancrage et conjugues
WO1998000171A2 (fr) * 1996-07-01 1998-01-08 Conjuchem, Inc. Excipients endogenes conjugues prolongeant la duree de vie des anti-thrombines

Also Published As

Publication number Publication date
CA2291066A1 (fr) 1999-09-30
IL133053A0 (en) 2001-03-19
EP1042003A1 (fr) 2000-10-11
JP2002512640A (ja) 2002-04-23
AU3452799A (en) 1999-10-18
WO1999048536A3 (fr) 2001-05-17
WO1999048536A2 (fr) 1999-09-30

Similar Documents

Publication Publication Date Title
AU748496B2 (en) Local delivery of long lasting therapeutic agents
US20030170250A1 (en) Local delivery of long lasting therapeutic agents
JP4675028B2 (ja) トリメチルロック型テトラパルテートプロドラッグ
US9993577B2 (en) Dissolvable hydrogel compositions for wound management and methods of use
US7799346B2 (en) Method of treatment directed to agent retention in biological tissues
US20180030091A1 (en) Collagen-binding synthetic peptidoglycans for use in vascular intervention
JP2021042238A (ja) バイオコンジュゲートおよびその使用
US20030035804A1 (en) Drug complex for treatment of metastatic prostate cancer
JP2009197023A (ja) ヒドロキシアパタイト標的化ポリ（エチレングリコール）および関連重合体
PT722470E (pt) Polimeros organicos multifuncionais
US11529424B2 (en) Synthetic bioconjugates
US20040047891A1 (en) Systems devices and methods for intrabody targeted delivery and reloading of therapeutic agents
CA2956137A1 (fr) Conjugues de ligands peptidiques se liant a icam/vcam et a la selectine
KR20200026918A (ko) 화학적으로 변형된 백본을 갖는 생체접합체
US20030108512A1 (en) Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of cancer
US20030195152A1 (en) Polymeric conjugates of antitumor agents
IL301558A (en) Peptide conjugates of SN38 are useful in cancer therapy
US20240252662A1 (en) Peptide drug conjugates specific to fibronectin isotypes for cancer therapy
JP2013523232A (ja) 被覆されたステントおよびタンパク質で被覆する方法
Huang Engineering RGD-Modified Liposomes for Targeted Drug Delivery to Activated Platelets

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)